Technical Analysis for RVX - Resverlogix Corp.

Grade Last Price % Change Price Change
F 0.055 0.00% 0.000
RVX closed unchanged on Wednesday, March 27, 2024, on 47 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Shooting Star Candlestick Bearish 0.00%
Lizard Bearish Bearish Day Trade Setup 0.00%
Expansion Breakdown Bearish Swing Setup 0.00%
Jack-in-the-Box Bearish Bearish Swing Setup 0.00%
Doji - Bearish? Reversal 0.00%
Doji - Bullish? Reversal 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish 0.00%
Shooting Star Candlestick Bearish 0.00%

   Recent Intraday Alerts

Alert Time
Reversed from Up about 17 hours ago
20 DMA Resistance about 17 hours ago
10 DMA Resistance about 17 hours ago
Rose Above 20 DMA about 18 hours ago
Rose Above 10 DMA about 18 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Resverlogix Corp. Description

Resverlogix Corp. is a clinical-stage biotechnology company. The Company is a development-stage company, which is engaged in developing apabetalone (RVX-208), a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (BET) inhibitor. Apabetalone is used for the treatment of patients with high-risk cardiovascular disease, (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer's disease and orphan diseases. Apabetalone is being investigated in a Phase III clinical trial for the secondary prevention of major adverse cardiovascular events (MACE) in high risk patients with diabetes mellitus and chronic kidney disease. The Company initiated a Phase III clinical trial BETonMACE with apabetalone in high-risk cardiovascular disease patients with low high-density lipoprotein. It focuses on conducting a proof-of-concept clinical trial in patients with Paroxysmal Nocturnal Hemoglobinuria. The Company has not generated any revenues.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Beta Clinic Biotechnology Disease RTT Medical Specialties Diseases Clinical Trial IPO Diabetes Alzheimer's Disease Chronic Condition Chronic Kidney Diabetes Mellitus Kidney Disease

Is RVX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.26
52 Week Low 0.055
Average Volume 38,363
200-Day Moving Average 0.079
50-Day Moving Average 0.064
20-Day Moving Average 0.059
10-Day Moving Average 0.058
Average True Range 0.004
RSI (14) 41.86
ADX 16.9
+DI 12.909
-DI 24.470
Chandelier Exit (Long, 3 ATRs) 0.054
Chandelier Exit (Short, 3 ATRs) 0.066
Upper Bollinger Bands 0.065
Lower Bollinger Band 0.054
Percent B (%b) 0.12
BandWidth 19.224
MACD Line -0.002
MACD Signal Line -0.002
MACD Histogram -0.0003
Fundamentals Value
Market Cap 11.98 Million
Num Shares 218 Million
EPS 0.51
Price-to-Earnings (P/E) Ratio 0.11
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.063
Resistance 3 (R3) 0.063 0.062 0.061
Resistance 2 (R2) 0.062 0.060 0.061 0.061
Resistance 1 (R1) 0.058 0.059 0.058 0.058 0.060
Pivot Point 0.057 0.057 0.056 0.056 0.057
Support 1 (S1) 0.053 0.055 0.053 0.053 0.050
Support 2 (S2) 0.052 0.054 0.051 0.049
Support 3 (S3) 0.048 0.052 0.049
Support 4 (S4) 0.048